Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors

Phase three clinical trial evidence suggests that colorectal cancers with the KRAS G13D mutation may benefit from EGFR inhibitors, like cetuximab, in contrast to the other most common KRAS mutations. A mechani...

Source: Cell Communication and Signaling - November 5, 2020 Category: Molecular Biology Authors: Thomas McFall, Noah K. Schomburg, Kent L. Rossman and Edward C. Stites Tags: Short report Source Type: research